Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01410799 · ClinicalTrials.gov registry record · Phase 2
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01410799: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT01410799 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01410799, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH) on the muscle, bone, and fat tissues of the body. GHRH stimulates the production of growth hormone (GH), which regulates the build up of many tissues in the body, including muscles and bones. Many elderly people have low levels of GH. The overall goal of this research is to determine the efficacy of GHRH to raise levels of GH and improve these body tissues. Healthy men and women age 65 and older will receive GHRH in four doses nightly for 12 weeks and assessed for changes in muscle strength, body mass, physical performance, and how the body uses sugar.
Interventions
- DRUG Growth Hormone Releasing Hormone (GHRH )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01410799
The ClinicalTrials.gov registry entry for NCT01410799 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Growth Hormone Releasing Hormone (GHRH ) is the first listed.
NCT01410799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01410799 about?
NCT01410799 is a clinical study titled "Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly". The purpose of the study is to evaluate the effect of a naturally occurring hormone, called Growth Hormone Releasing Hormone (GHRH) on the muscle, bone, and fat tissues of the body. GHRH stimulates the production of growth hormone (GH), which regulates the build up of many tissues in the body, inclu...
What is the current status of trial NCT01410799?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2011-05. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01410799?
The interventions under investigation include: Growth Hormone Releasing Hormone (GHRH ) (DRUG).
Who is sponsoring clinical trial NCT01410799?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.